1. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD) 
V.D. Nadarajah, M. van Putten, A. Chaouch, P. Garrood, V. Straub, H. Lochmüller, H.B. Ginjaar, A.M. Aartsma-Rus, G.J.B. van Ommen, J.T. den Dunnen, P.A.C. ’t Hoen 
Neuromuscular Disorders 
Volume 21, Issue 8, Pages (August 2011)
DOI: /j.nmd
Copyright © 2011 Elsevier B.V. Terms and Conditions

2. Fig. 1
Gene expression analysis of (a) Mmp9, (b) Timp1 and (c) Spp1 in exercised wt, exercised mdx and mdx. The bar charts show the mean levels of gene expression for each biomarker and the error bars indicate the standard deviation. One way ANOVA was used to determine differences between groups and the Student’s t-test was applied to determine significant differences between two groups, where P<0.01 is considered highly significant, and P<0.05 is significant. The number of mice per group is five for wt and six for mdx.
Neuromuscular Disorders  , DOI: ( /j.nmd )
Copyright © 2011 Elsevier B.V. Terms and Conditions

3. Fig. 2
Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN and (d) CK in exercised wt and exercised mdx at 8 and 14weeks. The bar charts show the mean serum levels of each biomarker and the error bars indicate the standard deviation. One way ANOVA was used to determine differences between groups and the Student’s t-test was applied to determine significant difference between two groups, where P<0.01 is considered highly significant, and P<0.05 is significant. The number of mice per group is five for wt and six for mdx.
Neuromuscular Disorders  , DOI: ( /j.nmd )
Copyright © 2011 Elsevier B.V. Terms and Conditions

4. Fig. 3
Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN in DMD and control samples. The median levels are indicated by the horizontal lines bisecting the box plot, which shows the interquartile range. The upper and lower limit of the bars show the maximum and minimum values considered while the extreme values are indicated by ○. Student’s t-test was applied to determine significant difference between the two groups.
Neuromuscular Disorders  , DOI: ( /j.nmd )
Copyright © 2011 Elsevier B.V. Terms and Conditions

5. Fig. 4
Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN in nonambulant, ambulant and control samples. The median levels are indicated by the horizontal lines bisecting the box plot, which shows the interquartile range. The upper and lower limit of the bars show the maximum and minimum values considered while the extreme values are indicated by ○. One way ANOVA was used to determine differences between groups and the Student’s t-test was applied to determine significant difference between two groups.
Neuromuscular Disorders  , DOI: ( /j.nmd )
Copyright © 2011 Elsevier B.V. Terms and Conditions

6. Fig. 5
Serum levels of (a) MMP-9, (b) TIMP-1, (c) OPN for the longitudinal DMD patient cohort. The mean serum levels of nine DMD patients were plotted over 2, 3 or 4 time points depending on patient sample availability. The time points are represented as the patient’s age.
Neuromuscular Disorders  , DOI: ( /j.nmd )
Copyright © 2011 Elsevier B.V. Terms and Conditions